Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs)-MedSci.cn

Antitumor activity of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody drug conjugate (ADC) across a diverse panel of breast cancer (BC) patient-derived xenografts (PDXs)

Odena, A; Monserrat, L; Braso-Maristany, F; Guzman, M; Grueso, J; Rodriguez, O; Scaltriti, M; Chandarlapaty, S; Qiu, Y; Koyama, K; Oliveira, M; Prat, A; Serra, V

CANCER RESEARCH, 2022; 82 (4):

科室
- - 订阅+
  - 更多科室
工具
服务